🛡 Psychedelic Therapy Outcome Long-Term Follow-Up Simulator

Immediate Post-Treatment Response

Placeholder: rapid symptom drop is often seen within days of dosing.

• 24–72h: Response window (Placeholder timeframe)
• ~60%: Responders (Placeholder rate)
• Variable: Score drop (Placeholder magnitude)
• Low: Adverse events (Placeholder note)

Acute effects

Placeholder: session followed by short integration support period.

Baseline comparison

Placeholder: scores compared against pre-treatment severity baseline.

1-Month Follow-Up Assessment

Placeholder: first formal check to confirm gains are holding steady.

• High: Retention of gains (Placeholder estimate)
• ~90%: Follow-up rate (Placeholder completion)
• Minimal: Symptom rebound (Placeholder observation)
• 1–2: Support contacts (Placeholder count)

Integration check-in

Placeholder: brief interview assesses mood and functioning shifts.

Early warning signs

Placeholder: clinicians watch for early symptom creep here.

3–6 Month Durability Check

Placeholder: mid-range window tests whether the plateau is stable.

• ~3–4mo: Plateau length (Placeholder duration)
• ~45%: Stable responders (Placeholder share)
• ~30%: Partial relapse (Placeholder share)
• ~25%: Full relapse (Placeholder share)

Plateau dynamics

Placeholder: symptom curve typically flattens before any decline.

Risk stratification

Placeholder: lower initial response linked to earlier decline onset.

12-Month Long-Term Outcome

Placeholder: year-long view shows gradual decline in many cases.

• ~35%: Durable response (Placeholder rate)
• Variable: Score at 12mo (Placeholder trend)
• ~20%: Return to baseline (Placeholder share)
• Common: Repeat treatment (Placeholder note)

Long-term trajectory

Placeholder: single course rarely guarantees permanent remission.

Comparative context

Placeholder: outcomes vary versus standard maintenance pharmacotherapy.

Booster Session Consideration

Placeholder: decision point on scheduling a reinforcing booster dose.

• ~40%: Booster uptake (Placeholder estimate)
• High: Re-response rate (Placeholder after booster)
• 6–12mo: Typical timing (Placeholder window)
• 50%+: Risk threshold (Placeholder trigger)

Decision criteria

Placeholder: relapse risk score guides the booster recommendation.

Booster protocol

Placeholder: repeat session mirrors the original dosing structure.